Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19684931 | 0.89 | CSF1R (0.39) | RIPK1GPR119USP2SMN1; SMN2PDE4D | |
| SCHEMBL19684713 | 0.88 | RIPK1 (0.39) | RIPK1GPR119SCN9AUSP2SMN1; SMN2 | |
| SCHEMBL19684711 | 0.88 | PIK3CD (0.36) | RIPK1GPR119SCN9AUSP2SMN1; SMN2 | |
| SCHEMBL19684712 | 0.86 | SMN1; SMN2 (0.35) | RIPK1GPR119SCN9AUSP2SMN1; SMN2 | |
| SCHEMBL19684747 | 0.86 | PDE4D (0.37) | GPR119USP2SMN1; SMN2PDE4DPIK3CD | |
| SCHEMBL19684697 | 0.83 | CCNT1 (0.44) | RIPK1SMN1; SMN2PTGDR2 | |
| SCHEMBL19667153 | 0.81 | USP2 (0.43) | RIPK1GPR119USP2SMN1; SMN2MKNK1 | |
| SCHEMBL19679351 | 0.81 | USP2 (0.43) | RIPK1GPR119USP2SMN1; SMN2MKNK1 | |
| SCHEMBL19684987 | 0.76 | ESR2 (0.42) | GPR119SCN9AMKNK1PDE4DPTGDR2 | |
| SCHEMBL19684706 | 0.75 | ADORA1 (0.42) | GPR119MKNK1PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | RIPK1 3885/4885GPR119 3953/4885SCN9A 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.